Indications
Therapeutic Asset Ratings
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Adriamycin
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
P3
BB
(66)
Adriamycin
Classic Hodgkin Lymphoma
Michael Spinner, MD
P3
BB
(66)
Adriamycin
Endometrial Carcinoma
AstraZeneca
P3
BB
(66)
Adriamycin
HER2 Positive Breast Carcinoma
Shanghai JMT-Bio Inc.
P3
BB
(66)
Adriamycin
Inflammatory Breast Carcinoma
M.D. Anderson Cancer Center
P3
BB
(66)
Adriamycin
Kidney Cancer
Oliver Jonas
P3
BB
(66)
Adriamycin
Ovarian Clear Cell Adenocarcinoma
National Cancer Institute (NCI)
P3
BB
(66)
Adriamycin
Ovarian Endometrioid Adenocarcinoma
National Cancer Institute (NCI)
P3
BB
(66)
Adriamycin
Carcinoma Of Urethra
University of Southern California
P3
BB
(66)
Adriamycin
Sarcoma
City of Hope Medical Center
P3
BB
(66)
Adriamycin
Triple-Negative Breast Carcinoma
Yuan Yuan
P3
BB
(66)
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit
Disease Related To Hematopoietic Stem Cell Transplant
The First Affiliated Hospital of Soochow University
P3
BB
(66)
Apitegromab
Neuromuscular Disease
Scholar Rock, Inc.
P3
BB
(66)
Asparaginase
B-Cell Acute Lymphoblastic Leukemia
University of Washington
P3
BB
(66)
Aspirin
Breast Carcinoma
Mayo Clinic
P3
BB
(66)
Aspirin
Lynch Syndrome
M.D. Anderson Cancer Center
P3
BB
(66)
Astx727
Myelodysplastic Syndrome
Taiho Oncology, Inc.
P3
BB
(66)
Atorvastatin
Renal Cell Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P3
BB
(66)
Autologous Cd34+ Cells Isolated From Mobilised Peripheral Blood By Positive Selection, Modified By Crispr/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats/Crispr-Associated Protein 9) Mediated Gene Editing Consisting Of A Guide Rna (Grna) Introduced Transiently As Ribonucleoprotein (Rnp) Complex, Targeting The Erythroid Lineage-Specific Enhancer Region Of Bcl11A (B-Cell Lymphoma/Leukemia 11A). The Site-Specific Cleavage By Cas9 Forms A Double Strand Break (Dsb), Which Is Subsequently Repaired By Nonhomologous End-Joining (Nhej), Leading To The Transcriptional Repression Of Bcl11A, A Repressor Of ?-Globin Gene Transcription
Disease Of Genetic Or Genomic Mechanism
Vertex Pharmaceuticals Incorporated
P3
BB
(66)
Autologous Cd34+ Cells Isolated From Mobilised Peripheral Blood By Positive Selection, Modified By Crispr/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats/Crispr-Associated Protein 9) Mediated Gene Editing Consisting Of A Guide Rna (Grna) Introduced Transiently As Ribonucleoprotein (Rnp) Complex, Targeting The Erythroid Lineage-Specific Enhancer Region Of Bcl11A (B-Cell Lymphoma/Leukemia 11A). The Site-Specific Cleavage By Cas9 Forms A Double Strand Break (Dsb), Which Is Subsequently Repaired By Nonhomologous End-Joining (Nhej), Leading To The Transcriptional Repression Of Bcl11A, A Repressor Of ?-Globin Gene Transcription
Hemoglobinopathy
Vertex Pharmaceuticals Incorporated
P3
BB
(66)
Avutometinib
Ovarian Serous Adenocarcinoma
Verastem, Inc.
P3
BB
(66)
Axitinib
Kidney Neoplasm
Pfizer
P3
BB
(66)
Befotertinib
Non-Small Cell Lung Carcinoma
Hebei Medical University Fourth Hospital
P3
BB
(66)
Bendamustine
B-Cell Chronic Lymphocytic Leukemia
Mayo Clinic
P3
BB
(66)
Benzeneethanamine, N-Ethyl-?-Methyl-4-(Trifluoromethyl)-, Hydrochloride, (±)-
Lennox-Gastaut Syndrome
University of Chicago
P3
BB
(66)
Showing 2101 to 2125 of 42,301 assets
Previous
Page 85 of 1693
Next